The stock was in demand after the company received EIR from the USFDA for its API manufacturing facility located at Patalganga
Indoco Remedies announced that it has received a Certificate of EU GMP Compliance from the European Health Authorities for its sterile drug product manufacturing facility at Goa Plant II.